Supplier
Planned Parenthood Mar Monte, INC
Planned Parenthood Mar Monte, INC was paid $9.05M by Medicaid between Jan 2018 and Dec 2024, across 65 billing codes. Its largest line is J7307, Etonogestrel (contraceptive) implant system, including implant and supplies — 13% of everything it billed.
33Billing provider infoPLANNED PARENTHOOD MAR MONTE, INC
SAN JOSE, CA 95126
SAN JOSE, CA 95126
33aNPI1043263189assigned 05/18/2006
33bProvider typeNon-Pharmacy Dispensing Site
28Total paid$9.05M
24GClaims225,865
24DCodes billed65
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Non-Pharmacy Dispensing Site providers in California
Rank by total paid#5 of 22
Median peer was paid$112K
This provider vs. median81×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MOTSIFF, TOM controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,870 | $1.96M | |
| 2019 | 20,649 | $734K | |
| 2020 | 26,308 | $883K | |
| 2021 | 43,506 | $1.31M | |
| 2022 | 16,630 | $660K | |
| 2023 | 26,712 | $1.30M | |
| 2024incomplete | 54,190 | $2.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | 13% | 1,491 | 1,486 | $1.18M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 10% | 15,336 | 14,658 | $923K |
| S4993 | Contraceptive pills for birth control | 7.3% | 6,663 | 6,619 | $659K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.1% | 6,791 | 6,577 | $645K |
| J3490 | Unclassified drugs | 6.5% | 22,818 | 18,776 | $592K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 5.8% | 5,593 | 5,565 | $521K |
| J7304 | Contraceptive supply, hormone containing patch, each | 4.9% | 602 | 597 | $440K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 4.6% | 18,695 | 17,977 | $413K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.4% | 6,954 | 6,795 | $401K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 4.0% | 1,812 | 1,807 | $364K |
| 11981 | 3.0% | 1,545 | 1,540 | $272K | |
| 87806 | 2.9% | 15,558 | 13,683 | $262K |
53 more codes
| J7300 | Intrauterine copper contraceptive (paragard) | 2.6% | 356 | $234K |
| 99204 | Doctor's office visit, new patient (more involved) | 2.6% | 984 | $233K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | 2.5% | 348 | $228K |
| 58300 | 2.5% | 2,830 | $228K | |
| S0199 | Medically induced abortion by oral ingestion of medication including all associated services and supplies (e.g., patient counseling, office visits, confirmation of pregnancy by hcg, ultrasound to confirm duration of pregnancy, ultrasound to confirm completion of abortion) except drugs | 2.4% | 871 | $217K |
| 99201 | 1.8% | 2,280 | $162K | |
| 90651 | 1.6% | 580 | $145K | |
| 57454 | 1.1% | 1,976 | $103K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 5,025 | $85K |
| 11976 | <1% | 1,527 | $83K | |
| A4267 | Contraceptive supply, condom, male, each | <1% | 11,525 | $73K |
| 99402 | <1% | 2,015 | $64K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12,090 | $55K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,279 | $54K |
| 58301 | <1% | 2,057 | $51K | |
| 99401 | <1% | 2,162 | $41K | |
| 99403 | <1% | 774 | $34K | |
| 81025 | <1% | 15,087 | $34K | |
| S5000 | Prescription drug, generic | <1% | 3,980 | $29K |
| J7303 | Contraceptive supply, hormone containing vaginal ring, each | <1% | 152 | $29K |
| 59840 | <1% | 280 | $28K | |
| 99000 | <1% | 12,968 | $27K | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 2,109 | $27K |
| S0190 | Mifepristone, oral, 200 mg | <1% | 776 | $21K |
| 83986 | <1% | 8,734 | $18K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12,058 | $18K |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 6,669 | $17K |
| 11982 | <1% | 412 | $9K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 861 | $9K |
| 57460 | <1% | 50 | $6K | |
| Q3014 | Telehealth originating site facility fee | <1% | 473 | $6K |
| 81002 | <1% | 2,307 | $3K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 1,038 | $3K |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 224 | $2K |
| 85018 | <1% | 1,380 | $1K | |
| S0191 | Misoprostol, oral, 200 mcg | <1% | 948 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 317 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 391 | $1K |
| 99152 | <1% | 32 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $723.28 |
| T1014 | Telehealth transmission, per minute, professional services bill separately | <1% | 475 | $624.19 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 12 | $507.88 |
| 86901 | <1% | 168 | $219.45 | |
| Z7610 | <1% | 28 | $189.58 | |
| 99070 | <1% | 23 | $51.40 | |
| 90686 | <1% | 56 | $46.98 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 14 | $39.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13 | $19.00 |
| 3079F | 0% | 34 | $0.00 | |
| 3074F | 0% | 138 | $0.00 | |
| 1220F | 0% | 13 | $0.00 | |
| 3078F | 0% | 80 | $0.00 | |
| 3077F | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOTSIFF, TOM (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.